The Latest Breaking News from Moderna

The search continues at a brisk pace thanks to rapid developments in generating more potent computing power.

Moderna Inc (NASDAQ:MRNA) said a COVID-19 booster designed to target the Beta variant and the original coronavirus generated a better immune response against several virus variants, including Omicron. Moderna said the results were a good sign for the company's plans for future shots targeting two COVID-19 variants. The company said the bivalent…

Researchers from King's College London are working on regenerating damaged hearts in the hope of developing a cure for heart attacks - with human trials set to begin within two years.

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Britain's medicines regulator approved the use of Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine in children between six and 11 years. The Medicines and Healthcare products Regulatory Agency (MHRA) said the approval was granted after Moderna's vaccine, known as Spikevax, met the required safety, quality, and effectiveness standards. Read Next: Why Did Moderna Recall Thousands Of COVID-19…

The vaccine's rollout still depends on the verdict of the Joint Committee on Vaccination Immunisation.

A decision on whether it will be offered still has to be made

‘Spikevax’ jab declared ‘safe and effective’ for this age group

The vaccine will still need to be considered by the Joint Committee on Vaccination and Immunisation to determine if it will be rolled out